Is a novel podophyllotoxin-derived compound GL331 more potent than its congener VP-16 in killing refractory cancer cells?
GL331's overriding drug resistance and higher cancer cell-killing activity suggest its superiority in clinical cancer therapy.
Differences in the GS composition between malignant and benign gallbladder patients may provide useful clues to the etiopathogenesis of GBC. These clues could lead to the identification of patients with GS in vivo who are at high risk of developing GBC, and advocate prophylactic cholecystectomy to prevent GBC.